ArticleChinese medical journal pulmonary and critical care medicine2025
Burden of chronic respiratory diseases and their attributable risk factors in 204 countries and territories, 1990-2021: Results from the global burden of disease study 2021.
Article in Chinese medical journal pulmonary and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- WeChat-assisted strategies for personalized health management in patients with AECOPD: A randomized controlled trial.PloS one · 2025Trial
- Lack of guidelines for cold exposure among vulnerable outdoor workers.International journal of circumpolar health · 2026Review
- Characteristics, prognosis, and risk factors for relapse in patients with cryptogenic organizing pneumonia: A prospective cohort study in China.Chinese medical journal · 2026Article
- Advances in metabolic reprogramming of pulmonary fibrosis.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Local administration of polymyxin B-conjugated Akkermansia muciniphila outer membrane vesicles attenuate asthma by suppressing M2 macrophage polarization.Science China. Life sciences · 2026Article
- Irisin maintains ER homeostasis and activates AMPK via integrin αVβ5 to attenuate CSE + LPS-induced emphysema and inflammation.Respiratory research · 2026Article
- Estrogen receptor β regulates sex-dependent airway mechanics and inflammation in a murine model of allergen exposure.Physiological reports · 2026Article
- Association between intrinsic capacity and chronic lung disease among middle-aged and older adults: evidence from CHARLS and ELSA.BMC public health · 2026Article
- Endothelial cell senescence shapes T cell activity in late-stage of chronic obstructive pulmonary disease.Cell death discovery · 2026Article
- Global, regional, and national burden of lower respiratory infections attributable to secondhand smoke exposure: Trends from 1990-2021 and projections to 2035.Chinese medical journal · 2026Article
- Welding Fumes in a Chinese Shipyard: Exposure Characteristics and Occupational Health Risk Assessment.Toxics · 2026Article
- Chronic Obstructive Pulmonary Disease as an Independent Predictor of Left Main Coronary Artery Disease.Medical sciences (Basel, Switzerland) · 2026Article
- Visceral fat metabolism score and cardiovascular-kidney-metabolic syndrome stages in all-cause and cause-specific mortality: insights from UK Biobank.Nutrition & metabolism · 2026Article
- Factors associated with life-space mobility in older adults with chronic respiratory disease: IMIAS study.Frontiers in rehabilitation sciences · 2026Article
- Time to first cigarette after waking and risk of incident chronic respiratory diseases in males: A prospective national cohort study.Tobacco induced diseases · 2026Article
- Residential Green and Blue Space, the Natural Environment, Genetic Susceptibility, and Incident COPD.International journal of chronic obstructive pulmonary disease · 2026Article
- Relationship between cathepsin K and extracellular matrix dynamics: a comprehensive review.Frontiers in oncology · 2026Review
- The burden of chronic respiratory disease in Western Pacific Region from 1990 to 2021: a systematic analysis for the global burden of disease study 2021.BMC public health · 2025Article
- Letter to the editor regarding: 'global, regional, and national burden of chronic respiratory diseases, 1990-2021 and predictions to 2035: analysis of data from the global burden of disease study 2021'.Annals of medicine · 2025Article
- Global, regional, and national burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2023, and projections to 2050: A systematic analysis for the Global Burden of Disease Study 2023.Chinese medical journal pulmonary and critical care medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic respiratory diseases (CRDs) remain a substantial global public health challenge, contributing significantly to morbidity and mortality worldwide. This study aimed to comprehensively characterize trends in CRD burden across various populations by examining differences by sex, age, and sociodemographic index (SDI). Methods: We performed a systematic analysis using data from the Global Burden of Disease (GBD) 2021 study, covering the period from 1990 to 2021 across 204 countries and territories. Estimates of age-standardized prevalence, mortality, disability-adjusted life years (DALYs), incidence, and annualized percentage changes for both 1990-2021 and 2019-2021 were calculated. Geographic and demographic variations were evaluated by age, sex, and SDI. The contributions of key risk factors-including tobacco use, ambient particulate matter (PM) pollution, household air pollution from solid fuels, and occupational exposure to PM, gases, and fumes-were also assessed. Results: In 2021, an estimated 468.3 million individuals globally were living with CRDs, with an age-standardized prevalence rate of 5785.4 per 100,000 population. CRDs accounted for 4.4 million deaths with age-standardized mortality rate of 53.6 per 100,000 population and 108.5 million DALYs with age-standardized DALY rate of 1294.6 per 100,000 population in the same year. Age-standardized prevalence rate decreased by 1.01 % from 1990 to 2021 but increased by 0.20 % from 2019 to 2021. From 2019 to 2021, the age-standardized incidence rate of CRDs increased slightly from 713.4 to 719.3 per 100,000 population, with an annualized percentage change of 0.41 %, while the age-standardized DALY rate continued to decline from 1321.9 to 1294.6 per 100,000 population, with an annualized percentage change of -1.04 %. Although the age-standardized mortality rate declined by 1.46 % over the full period, the absolute number of deaths rose as a result of demographic shifts, including population growth and aging. Globally, tobacco use remained the predominant risk factor, while household air pollution from solid fuels was the leading contributor to DALYs and mortality in low- and low-middle SDI countries. Conclusion: The global burden of CRDs remains both substantial and dynamic, underscoring the continued influence of risk factors such as tobacco use and household air pollution. These findings emphasize the urgent need for targeted public health interventions and more equitable healthcare resource allocation, particularly in low- and middle-SDI regions. Strengthened surveillance systems, improved access to care, and integrated strategies addressing both established and emerging risk factors are essential for reducing the global impact of CRDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.